Compare Medpace Holdings Inc (MEDP) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Sprott Uranium Miners ETF — how do they compare? Medpace Holdings Inc trades at $523.05 (market cap $15.35B), while Sprott Uranium Miners ETF trades at $48.4. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| MEDP | URNM | |
|---|---|---|
Market Cap | $15.35B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $620.59 | $83.99 |
52-Week Low | $308.88 | $44.14 |
Enterprise Value | $14.82B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $534.31, down 0.64% today, with a bullish technical signal from moving averages. The company shows strong profitability with 17.19% net margin and 77.25% ROE, though valuation ratios appear elevated with P/E of 33.83. Recent earnings have consistently beaten expectations, and 2026 projections indicate continued revenue growth to $2.7B. However, the stock faces headwinds from a class action lawsuit and mixed analyst sentiment with only 21% buy ratings.
MEDP presents a mixed outlook with strong fundamental performance offset by valuation concerns and legal risks. The stock trades above the consensus price target of $497, suggesting limited near-term upside. Earnings consistency and CRO industry demand provide support, but investors should weigh the high valuation against litigation overhang and cautious Wall Street positioning.
URNM trades at $48.25, up 0.06% on the day, while technical indicators signal a bearish trend with moving averages unanimously negative. The uranium ETF benefits from strong thematic tailwinds as AI-driven power demand boosts nuclear energy prospects, though key financial ratios are unavailable for this fund. Recent news highlights uranium's role in the AI infrastructure build-out, with URNM gaining 26% year-to-date according to 24/7 Wall Street on 2026-04-29.
The long-term outlook for URNM is positive due to structural uranium supply deficits and rising nuclear power adoption, but near-term price volatility and concentrated miner exposure pose risks. Investors face a trade-off between high growth potential and sector-specific cyclicality, with technical weakness suggesting cautious entry timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
